drugset / Trial / NCT01585025

Obeticholic Acid in Bile Acid Diarrhoea

NCT01585025 ↗

Phase 2 Completed 35 enrolled Imperial College Healthcare NHS Trust
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The investigators propose to develop studies of obeticholic acid (OCA) in patients with bile acid diarrhoea. OCA is a semisynthetic bile acid, also known as 6αethylchenodeoxycholic acid or INT747,and is a potent farnesoid X receptor (FXR) agonist. Preliminary data suggests that patients with bile acid diarrhoea have impaired production of the ileal hormone Fibroblast Growth Factor 19 (FGF19). FGF19 is stimulated by FXR agonists, and regulates bile acid synthesis. This study is a pilot, proof-of-concept, open-label study to investigate whether OCA can stimulate FGF19 in bile acid diarrhoea patients to provide a safe and effective treatment.

Timeline

Start
2012-04
Primary completion
2014-01
Completion
2014-02

Outcome

Met primary endpoint

paper In primary bile acid diarrhoea, obeticholic acid increased median fasting FGF19 (133-237 pg/mL, P = 0.007) PMID 25329562 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Obeticholic Acid Small molecule 25 mg Oral